# A Phase III Study of Jaktinib in Adults With Moderate and Severe Atopic Dermatitis

> **NCT05526222** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Suzhou Zelgen Biopharmaceuticals Co.,Ltd** · enrollment: 443 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Jaktinib Hydrochloride Tablet

## Key facts

- **NCT ID:** NCT05526222
- **Lead sponsor:** Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-07-14
- **Primary completion:** 2026-06
- **Final completion:** 2026-09
- **Target enrollment:** 443 (ACTUAL)
- **Last updated:** 2026-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05526222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05526222, "A Phase III Study of Jaktinib in Adults With Moderate and Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05526222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*